Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing

M. S. Hershfield, John Callaghan, W. Tassaneeyakul, T. Mushiroda, C. F. Thorn, T. E. Klein, M. T M Lee

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B 58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

Original languageEnglish
Pages (from-to)153-158
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume93
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Allopurinol
Pharmacogenetics
HLA Antigens
Genotype
Guidelines
Drug Hypersensitivity Syndrome
Hyperuricemia
Stevens-Johnson Syndrome
Skin
Gout
Alleles
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing. / Hershfield, M. S.; Callaghan, John; Tassaneeyakul, W.; Mushiroda, T.; Thorn, C. F.; Klein, T. E.; Lee, M. T M.

In: Clinical Pharmacology and Therapeutics, Vol. 93, No. 2, 02.2013, p. 153-158.

Research output: Contribution to journalArticle

Hershfield, M. S. ; Callaghan, John ; Tassaneeyakul, W. ; Mushiroda, T. ; Thorn, C. F. ; Klein, T. E. ; Lee, M. T M. / Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing. In: Clinical Pharmacology and Therapeutics. 2013 ; Vol. 93, No. 2. pp. 153-158.
@article{ffe3bd7ac7dd492ba54fa946027a47ab,
title = "Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing",
abstract = "Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B 58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.",
author = "Hershfield, {M. S.} and John Callaghan and W. Tassaneeyakul and T. Mushiroda and Thorn, {C. F.} and Klein, {T. E.} and Lee, {M. T M}",
year = "2013",
month = "2",
doi = "10.1038/clpt.2012.209",
language = "English",
volume = "93",
pages = "153--158",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing

AU - Hershfield, M. S.

AU - Callaghan, John

AU - Tassaneeyakul, W.

AU - Mushiroda, T.

AU - Thorn, C. F.

AU - Klein, T. E.

AU - Lee, M. T M

PY - 2013/2

Y1 - 2013/2

N2 - Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B 58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

AB - Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCARs), which include drug hypersensitivity syndrome, Stevens Johnson syndrome, and toxic epidermal necrolysis. A variant allele of the human leukocyte antigen (HLA)-B, HLA-B 58:01, associates strongly with allopurinolinduced SCAR. We have summarized the evidence from the published literature and developed peer-reviewed guidelines for allopurinol use based on HLA-B genotype.

UR - http://www.scopus.com/inward/record.url?scp=84872678727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872678727&partnerID=8YFLogxK

U2 - 10.1038/clpt.2012.209

DO - 10.1038/clpt.2012.209

M3 - Article

VL - 93

SP - 153

EP - 158

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -